IMAPAC Glossary

Quality control sampling defines the procedures for selecting representative samples to verify that materials and products meet established quality specifications.

A Quality Management System (QMS) is the organisational framework of processes and procedures used to ensure consistent product quality and regulatory compliance.

Quality Risk Management is a systematic approach for identifying, evaluating, controlling and reviewing risks that may affect pharmaceutical product quality.

A quality system audit systematically evaluates quality management systems to verify compliance with regulatory requirements and internal quality standards.

A Quality Target Product Profile (QTPP) is a prospective summary of the quality characteristics required to ensure a pharmaceutical product meets its intended clinical objectives.

A quality unit is the organisational function responsible for overseeing quality systems, compliance and product quality throughout pharmaceutical operations.

Quantitative analysis uses analytical methods to accurately measure the amount or concentration of specific substances within a sample.

Quantitative metabolism prediction estimates the rate and extent of drug metabolism using experimental data or computational modelling.

Quantitative PCR (qPCR) is a molecular technique that measures nucleic acid quantities in real time during DNA amplification.

Quantitative Structure-Activity Relationship (QSAR) uses mathematical models to predict the biological activity or toxicity of compounds from their chemical structures.

Quarantine is the controlled storage status assigned to materials or products to prevent their use or distribution until they have been evaluated and approved.

Quartile analysis methodology divides datasets into four equal groups to evaluate data distribution, variability and statistical trends.

Quaternary structure characterisation analyses the arrangement and interactions of multiple protein subunits to confirm structural integrity and biological function.

Quenching efficiency assessment evaluates how effectively a quencher suppresses fluorescence or other signals during analytical or biochemical assays.

Query response effectiveness measures how accurately, consistently and promptly responses resolve scientific, regulatory or clinical information requests.

A quick dissolution test rapidly evaluates the release of an active pharmaceutical ingredient from a dosage form as part of quality assessment.

A radiolabelled tracking study uses radioactive labels to monitor the distribution, metabolism or elimination of compounds within biological systems.

A radioligand binding assay is an analytical technique that uses radioactively labelled ligands to quantify interactions between biological targets and their binding molecules.

Raman Spectroscopy is a vibrational spectroscopic technique that characterises molecular structure and composition by measuring the inelastic scattering of light from chemical bonds.

A randomised controlled trial (RCT) is the gold-standard clinical study design that randomly assigns participants to treatment groups to minimise bias and evaluate therapeutic interventions.

Real-World Evidence (RWE) comprises clinical insights derived from real-world healthcare data collected outside traditional clinical trial settings during routine patient care.

Receptor occupancy is the proportion of target receptors bound by a drug, providing a mechanistic measure of target engagement and pharmacological activity.

Receptor occupancy theory explains how the proportion of receptors bound by a drug influences the magnitude of its pharmacological effect.

Receptor tyrosine kinases (RTKs) are transmembrane proteins that regulate cell growth, differentiation, metabolism and survival through ligand-activated signalling pathways.

Recombinant antibodies are genetically engineered immunoglobulins produced using recombinant DNA technology, providing greater control over antibody structure, function and manufacturing consistency.

A recombinant protein is a protein produced through genetic engineering by expressing an inserted gene within a suitable host cell.

Redox potential is the tendency of a chemical species to gain or lose electrons, indicating its oxidising or reducing capacity in a given environment.

A reference standard is a highly characterised material used as a benchmark to verify the identity, quality, purity and strength of pharmaceutical substances.

Refractory disease is a condition that fails to respond adequately to standard treatment and continues to progress despite appropriate therapeutic intervention.

A regulatory compliance checklist provides a structured list of regulatory requirements used to verify adherence throughout product development and manufacturing.

Regulatory intelligence gathering systematically collects and analyses evolving regulatory information to support strategic planning and compliance.

Regulatory precedent navigation identifies and applies previous regulatory decisions to support product development, submission strategies and compliance planning.

Relative potency assessment compares the biological activity of a test product with a qualified reference standard to confirm consistent product performance.

Release testing comprises quality control tests performed before product distribution to confirm that a pharmaceutical batch meets predefined specifications.

Renal clearance is the volume of plasma from which a substance is removed by the kidneys per unit time through filtration, secretion and reabsorption.

A renal function monitoring protocol defines the clinical assessments and laboratory tests used to evaluate kidney function during therapeutic treatment.

A reporter gene encodes an easily detectable protein that enables researchers to monitor gene expression, promoter activity and other biological processes.

Rescue medication is a medicine used to provide rapid relief of acute symptoms or breakthrough episodes during ongoing treatment.

Residual Host Cell Protein (HCP) refers to protein impurities originating from production host cells that remain in recombinant biologic products after purification.

A respiratory adverse effect is an unwanted treatment-related effect involving the respiratory system, including changes in breathing, lung function or airway health.

Retention index calculation standardises chromatographic retention data to improve compound identification and comparison between analytical systems.

Reverse transcription is the enzymatic process of converting RNA into complementary DNA using reverse transcriptase enzymes.

Reversibility assessment determines whether treatment-related biological effects or adverse events resolve after discontinuation of the therapeutic product.

A ribosome is the cellular molecular machine responsible for translating messenger RNA into proteins during protein synthesis.

A risk-based approach prioritises decisions, controls and resources according to the likelihood and impact of risks affecting product quality, safety or regulatory compliance.

RNA Interference (RNAi) is a natural gene silencing mechanism in which small RNA molecules suppress specific gene expression by targeting complementary messenger RNA for degradation or translational inhibition.

Scaffold proteins are molecules that organise signalling complexes by bringing together multiple interacting proteins to regulate cellular communication pathways.

Scale-up is the process of increasing manufacturing from laboratory or pilot scale to commercial production while maintaining product quality and process consistency.

Secondary structure refers to local protein folding patterns, including alpha helices and beta sheets, stabilised primarily by hydrogen bonding.

Sensitive subgroup identification determines patient populations that may respond differently to treatment because of clinical, genetic or demographic characteristics.

A sepsis management protocol defines evidence-based procedures for the early recognition, treatment and monitoring of patients with sepsis.

Serialisation is the assignment of unique identifiers to individual medicine packs to enable product traceability throughout the pharmaceutical supply chain.

Shear stress is the mechanical force generated by fluid movement that can affect cells, proteins and pharmaceutical formulations during manufacturing.

Shelf-life prediction modelling estimates the period during which a pharmaceutical product is expected to remain within specification under defined storage conditions.

A signal peptide is a short amino acid sequence that directs newly synthesised proteins to their correct cellular destination.

Signal transduction comprises the cellular signalling pathways that convert external signals into intracellular biological responses through sequential molecular events.

Single-cell analysis comprises technologies that measure molecular characteristics in individual cells, revealing cellular differences hidden within bulk populations.

A single nucleotide polymorphism (SNP) is a DNA sequence variation involving a single nucleotide difference at a specific genomic position.

Site-directed mutagenesis is a molecular biology technique that introduces precise DNA sequence changes to investigate or engineer protein function.

Size-exclusion chromatography (SEC) separates molecules according to their hydrodynamic size using porous stationary phases during chromatographic analysis.

Solubility-limiting bioavailability occurs when poor drug solubility restricts absorption and reduces the amount of active ingredient reaching systemic circulation.

Somatic cell therapy uses living cells that have been processed outside the body to treat disease through mechanisms such as tissue repair or immune modulation.

Specific activity is the biological activity of a substance per unit mass of protein, providing a measure of its purity and functional potency.

Stability testing evaluates how pharmaceutical products change over time under defined environmental conditions to establish shelf life and storage requirements.

A stable cell line is a genetically engineered cell population that maintains long-term expression of an inserted gene through stable chromosomal integration.

Steady-state concentration achievement is the point at which drug administration and elimination are balanced, producing stable systemic drug concentrations.

Stem cell differentiation is the biological process through which stem cells develop into specialised cell types with distinct structures and functions.

Stem cell therapy uses stem cells to repair, replace or regenerate damaged tissues for the treatment of disease.

Steric hindrance effect describes how the physical size or spatial arrangement of atoms limits molecular interactions or chemical reactions.

Sterile describes the complete absence of viable micro-organisms, ensuring products are free from microbial contamination for safe clinical use.

Sterility Assurance Level (SAL) is the statistical probability that a sterilised product remains free from viable micro-organisms after sterilisation.

Structural isomer differentiation distinguishes compounds with identical molecular formulas but different structural arrangements using analytical techniques.

Subclinical toxicity detection identifies early biological changes indicating toxicity before clinical symptoms become apparent.

Subcutaneous refers to the tissue layer beneath the skin and is a common route for administering injectable medicines.

Substrate selectivity assessment evaluates the preference of an enzyme or transporter for specific substrates to understand biological activity and specificity.

Substrate specificity is the selective ability of an enzyme or binding protein to recognise and interact with particular molecular substrates.

Synthetic biology applies engineering principles to design and construct new biological systems, pathways or organisms with defined functions.

Systems biology is an integrated approach that studies biological systems by combining experimental data with computational modelling to understand complex interactions.

Tandem mass spectrometry (MS/MS) is an analytical technique that performs sequential mass analysis to identify and quantify molecules with high sensitivity and specificity.

A target is the specific biological molecule or pathway that a therapeutic agent interacts with to produce its intended pharmacological effect.

Targeted therapy selectively acts on specific molecular targets or disease pathways to improve treatment precision while reducing effects on healthy tissues.

A target engagement biomarker demonstrates that a therapeutic product has successfully interacted with its intended biological target in vivo.

A teratogenicity assessment protocol defines the methods used to evaluate the potential of a substance to cause developmental abnormalities during pregnancy.

Therapeutic describes an intervention, product or approach intended to treat, prevent or alleviate disease or medical conditions.

A therapeutic antibody is an engineered antibody developed for medical use to treat disease through highly specific immune or molecular targeting mechanisms.

A therapeutic drug monitoring strategy defines when and how drug concentrations should be measured to optimise efficacy and minimise toxicity.

Therapeutic drug monitoring (TDM) is the clinical measurement of drug concentrations to optimise dosing while maximising efficacy and minimising toxicity.

The therapeutic index is the ratio between a drug's toxic dose and effective dose, indicating its margin of safety.

Therapeutic index determination calculates the relationship between effective and toxic doses to assess the safety margin of a therapeutic product.

Therapeutic Protein refers to a biologic medicine composed of engineered or purified proteins that treats disease through replacement, immune modulation, enzymatic activity or receptor binding.

Therapeutic Vaccine refers to a vaccine designed to treat an existing disease by stimulating immune responses against cancer cells, chronic infections or other disease-associated antigens.

Therapeutic Window is the range of drug doses or exposures that provides clinical benefit without causing unacceptable toxicity.

Thermal Stability is the ability of a pharmaceutical product to retain its structure, potency and quality when exposed to temperature variations during manufacture, storage or transport.

Time-dependent pharmacokinetics describes changes in pharmacokinetic behaviour over time caused by factors such as enzyme induction, inhibition or physiological adaptation.

Tissue distribution imaging visualises the localisation and concentration of therapeutic compounds within tissues using imaging technologies or labelled tracers.

Titer is the concentration of a biological product in fermentation broth or cell culture medium, indicating process productivity and manufacturing performance.

Titration schedule optimisation determines the most appropriate rate of dose adjustment to maximise efficacy while minimising adverse effects.

Toll-like Receptors (TLRs) are pattern-recognition receptors that detect microbial components and initiate innate immune signalling, inflammation and adaptive immune activation.

Topical describes a medicine or treatment applied directly to the skin, mucous membranes or another body surface for local or systemic effects.

Toxicity is the capacity of a chemical, physical or biological agent to cause harmful effects in living organisms.